Could 3D Signatures Inc See a Reversal After This Very Strong Session?

 Could 3D Signatures Inc See a Reversal After This Very Strong Session?

The stock of 3D Signatures Inc (CVE:DXD) is a huge mover today! About 34,720 shares traded hands. 3D Signatures Inc (CVE:DXD) has risen 6.00% since October 29, 2016 and is uptrending. It has underperformed by 0.01% the S&P500.
The move comes after 9 months positive chart setup for the $39.06M company. It was reported on Nov, 28 by We have $0.91 PT which if reached, will make CVE:DXD worth $1.17M more.

More notable recent 3D Signatures Inc (CVE:DXD) news were published by: which released: “3D Signatures Inc. Announces Closing of Qualifying Transaction” on September 09, 2016, also with their article: “3D Signatures Inc. Appoints Jason Flowerday as New CEO” published on September 27, 2016, published: “3D Signatures Inc. and Plicit Capital Corp. Increase Minimum Financing and …” on May 26, 2016. More interesting news about 3D Signatures Inc (CVE:DXD) were released by: and their article: “3D Signatures Inc. Introduces Business Advisory Board and Celebrates Recent …” published on October 27, 2016 as well as‘s news article titled: “3D Signatures Inc. Commences Trading September 13th Under the Symbol (TSX …” with publication date: September 12, 2016.

3D Signatures Inc, formerly Plicit Capital Corp, is a Canada personalized medicine firm with a software platform based on the three-dimensional analysis of telomere organization. The company has a market cap of $39.06 million. The Company’s software technology and prognostic methodology targets various diseases that demonstrate genomic instability, including cancer and neurological disorders. It currently has negative earnings. It is engaged in developing over five diagnostic and prognostic products for cancers and neurological disorders, including 3D Telo-PC, 3D Telo-RS, 3D Telo-MM, 3D Telo-BC, 3D Telo-LC and 3D Telo-AD.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment